

Company Overview

CollPlant is a regenerative medicine company focused on 3D bioprinting of tissues and organs, and on developing and commercializing tissue repair products for orthobiologics, and advanced wound care markets. Our products are based on our rhCollagen (recombinant human collagen) that is produced with CollPlant's proprietary plant based genetic engineering technology.

Our products address indications for diverse fields of organ and tissue repair, and are ushering in a new era in regenerative medicine. Our flagship rhCollagen BiInk product line is ideal for 3D bioprinting of tissues and organs, and our unique VergeNix line of rhCollagen products includes a soft tissue repair matrix for treating tendinopathy and a wound repair matrix to promote a rapid optimal healing of acute and chronic wounds.

CollPlant Announces Approval of Its rhCollagen Manufacturing Facility by European Union Notified Body

Feb 19 2019, 6:00 AM EST

Stock Overview

Symbol	CLGN
Exchange	Nasdaq
Market Cap	21.15m
Last Price	\$5.55
52-Week	\$3.13 - \$8.73

02/20/2019 03:58 PM EST

Investor Relations

Eran Rotem
Deputy CEO & CFO
T: +972 (73) 2325612
F: +972 (73) 2325602
eran@collplant.com

Corporate Profile®
Laurel Moody
1185 Avenue of the Americas 3rd
Floor
New York, NY 10036
T: +1 212 931 8787 Ext 101

Cybele Holdings Ltd.
Yael Schnitzer
T: +972(3)5755123
yael@cybele.co.il

Management Team

Yehiel Tal

Chief Executive Officer

Prof. Oded Shoseyov

Founder, Chief Scientific Officer

Eran Rotem, CPA

Deputy CEO and Chief Financial Officer

Dr. Nadav Orr

Vice President, Research and Development

Dr. Ilana Belzer

Chief Operating Officer

Dr. Philippe Bensimon

Vice President, Regulatory Affairs and Quality Assurance

CollPlant Holdings Ltd.

3 Sapir Street
Weizmann Science Park
Ness Ziona 74140
Israel

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.